Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11769
Title: Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines.
Authors: Cheung, Ada S;Pattison, D;Bretherton, I;Hoermann, Rudolf;Lim Joon, Daryl;Ho, E;Jenkins, T A;Hamilton, E J;Bate, K;Chan, I;Zajac, J D;Grossmann, Mathis
Affiliation: Department of Medicine Austin Health, The University of Melbourne, Heidelberg, Vic., Australia
Issue Date: 20-May-2013
Citation: Andrology 2013; 1(4): 583-9
Abstract: Our objective was to evaluate the effectiveness of implementing standardized guidelines to mitigate metabolic and bone side effects of androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer. We conducted a 2-year prospective cohort study at a tertiary referral teaching hospital. Overall, 236 men (mean age 69.8 ± 7.1) commencing ADT for non-metastatic prostate cancer attended a baseline clinic visit between 2007 and 2011, and 153 men were eligible for follow-up after 2 years of continuous ADT. Of these, 113 men had data available for analysis at 2 years. At baseline, 87% of the men were overweight or obese, 61% had hypertension, 56% had hypercholesterolaemia, 27% prior cardiovascular disease, 11% osteoporosis and 40% osteopaenia. After 2 years of ADT, there was an increase in waist circumference (+2.8 ± 6.3 cm, p = 0.002), and, in men without diabetes, in HbA1c (+0.13 ± 0.34%, p = 0.019). Despite this, due to treatment, there were significant reductions in total cholesterol (-0.35 ± 1.00 mmol/L, p < 0.001), and blood pressure (systolic -7.6 ± 19.3 mmHg; diastolic -4.7 ± 11.6 mmHg, p < 0.001). After 2 years, men not receiving anti-resorptive therapy experienced a significant decline in lumbar spine (-0.042 ± 0.134 g/cm(2) , p = 0.012) and total hip bone mineral density (BMD) (-0.026 ± 0.036 g/cm(2) , p < 0.001), whereas bisphosphonate treatment maintained stable BMD. Prevalence of anaemia increased from 13.8 to 32.5%. Older age independently predicted a greater drop in haemoglobin (p = 0.005). We conclude that a structured approach to assess and treat men undergoing ADT effectively improves cardiovascular risk factors and prevents bone decay. Larger studies are needed to determine effects on cardiovascular outcomes, fracture prevention and survival.
Internal ID Number: 23686896
URI: http://ahro.austin.org.au/austinjspui/handle/1/11769
DOI: 10.1111/j.2047-2927.2013.00093.x
URL: http://www.ncbi.nlm.nih.gov/pubmed/23686896
Type: Journal Article
Subjects: Aged
Androgen Antagonists.adverse effects
Antineoplastic Agents, Hormonal.adverse effects
Biological Markers.blood
Bone Density.drug effects
Cardiovascular Diseases.blood.chemically induced.epidemiology.prevention & control
Comorbidity
Guideline Adherence
Hospitals, Teaching
Humans
Male
Middle Aged
Osteoporosis.chemically induced.epidemiology.prevention & control.radiography
Practice Guidelines as Topic
Prevalence
Prospective Studies
Prostatic Neoplasms.drug therapy.pathology
Risk Factors
Tertiary Care Centers
Time Factors
Treatment Outcome
Victoria.epidemiology
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.